HPV seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected MSM
Menée aux Pays-Bas auprès de 664 participants masculins homosexuels d'âge supérieur à 18 ans, cette étude évalue l'association entre une infection par le VIH, une infection par le papillomavirus humain et le risque de cancer de l'anus ou du pénis
Background: We assessed human papillomavirus (HPV) seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected men who have sex with men (MSM). Methods: MSM aged ≥18 years were recruited in Amsterdam, the Netherlands (2010-2011), and followed up semi-annually. Antibodies against 7 high-risk HPV types in baseline and 12-month serum samples were tested using a multiplex immunoassay. Baseline, 6-, and 12-month anal and penile samples were tested for HPV DNA using the SPF10-PCR DEIA/LiPA25 system. Statistical analyses were performed using logistic regression with generalized estimating equations. Results: Of 644 MSM included in the analysis, 245 (38%) were HIV-infected. Median age was 38 years for HIV-negative and 47 years for HIV-infected MSM (P<0.001). Seroconversion against ≥1 of the 7 HPV types was observed in 74/396 (19%) HIV-negative and 52/223 (23%) HIV-infected MSM at risk (P=0.2). Incident (adjusted odds ratio (aOR) 2.0; 95%CI 1.1-3.4) and persistent (aOR 3.7; 95%CI 1.5-9.5) anal HPV infections were independently associated with type-specific seroconversion in HIV-negative MSM. In HIV-infected MSM, there was a non-significant positive association between penile HPV infection at any time point and seroconversion (aOR 1.7; 95%CI 0.9-3.2). Conclusions: Incident or persistent anal HPV infection was an independent determinant of seroconversion in HIV-negative MSM. Impact: Our data support that seroresponse may vary per anatomical site, and that persistent HPV infections are more likely to elicit a detectable humoral immune response.